Winthrop Pharmaceuticals UK Ltd

One Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 554 831
E-mail: UK-medicalinformation@sanofi-aventis.com
Medical Information Direct Line: +44 (0)1483 554 101
Medical Information Fax: +44 (0)1483 554 831

Summary of Product Characteristics last updated on the eMC: 17/05/2011
SPC Flagyl Tablets 200 mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/05/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   11-May-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



section 4.8 (undeisrable effect)

addition of aseptic meningitis and optic neuropathy/neuritis

 

Updated on 25/03/2011 and displayed until 17/05/2011
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   16-Mar-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


Section 4.4 - brought in line with CCDS
- addition of info about use in patients with active or chronic severe peripheral or central nervous system disease due to the risk of neurological aggravation, as well side effects to look out for.
- warning about darkening of urine
- Cefuroxime info added and mutagenic potential.
Updated on 09/02/2011 and displayed until 25/03/2011
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   31-Jan-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 4.8 - Updated in line with company core data sheet:

Immune system disorders: fever added
Psychiatric disorders: depressed mood added
Eye disorders: clarification of duration of side effect
Gastrointestinal disorder: clarification of GI disturbances
Skin and subcut tissue disorders: flushing added
Updated on 19/01/2011 and displayed until 09/02/2011
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   04-Jan-2011
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Change to section 4.1 to add the following wording: Flagyl is indicated in adults and children for the following instructions. Licensed indications remain unchanged.

Also following text added under this section: Considerations should be given to official guidance on the appropriate use of antibacterial agents.

Section 4.2: there are changes to the information included for dosage and administeration in children.

For prophylaxis against anaerobic infection the following guidance is provided or children:
Children < 12 years: 20-30mg/kg as a single dose given 1-2 hours before surgery. Newborns with a gestation age < 40 weeks: 10mg/kg body weight as a single dose before operation.

Previously the SPC just advised a 7.5mg/kg 8 hourly dose.

For the treatment of established anaerobic infection- where previsouly the SPC just advised a 7.5mg/kg 8 hourly dose, guidance has been ammended to;

Children > 8 weeks to 12 years of age: The usual daily dose is 20-30mg/kg/day as a single dose or divided into 7.5mg/kg every 8 hours. The daily dose may be increased to 40mg/kg, depending on the severity of the infection. Duration of treatment is usually 7 days.

Children < 8 weeks of age: 15mg/kg as a single dose daily or divided into 7.5mg/kg every 12 hours. In newborns with a gestation age < 40 weeks, accumulation of metronidazole can occur during the first week of life, therefore the concentrations of  metronidazole in serum should preferable be monitored after a few days therapy.

information for use in urogenital trichomoniasis has been updated to:

 

Duration of dosage in

Adults and children over

Children

 

days

10 years

7 to 10 years

3 to 7 years

1 to 3 years

Urogenital trichomoniasis

Where re-infection

is likely, in adults

the consort should

receive a similar course of treatment concurrently

7

 

 

 

or

2000mg as a single dose or 200 mg three times daily
or

 

 

 

40mg/kg orally as a single dose or 15-30 mg/kg/day divided in 2-3 doses; not to exceed 2000mg/dose

5- 7

400mg twice daily

 

 

 


Guidance for use in Giardiasis has changed to:

Giardiasis

3

2000mg once daily

or

1000mg once daily

600-800 mg once daily

 

500 mg once daily

5

400mg three times daily

or

 

 

 

7-10

500mg twice daily

 

 

 

Alternatively, as expressed in mg per kg of body weight:

15-40mg/kg/day divided in 2-3 doses.


and new advise added for the eradication of helicobacter pylori in paediatric patients;As a part of a combination therapy, 20mg/kg/day not to exceed 500mg twice daily for 7-14 days. Official guidelines should be consulted before initiating therapy.

Section 4.5: following wording added- Psychotic reactions have been reported in patients who were using metronidazole and disulfiram concurrently.

Section 4.9- wording ammended to:

Single oral doses of metronidazole, up to 12g have been reported in suicide attempts and accidental overdoses. Symptoms were limited to vomiting, ataxia and slight disorientation. There is no specific antidote for metronidazole overdosage. In cases of suspected massive overdose, symptomatic and supportive treatment should be instituted.


Section 10: date changed to 04/01/2011
Updated on 24/09/2008 and displayed until 19/01/2011
Reasons for adding or updating:
  • Addition of separate SPCs covering individual presentations
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   27-Aug-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company


Completely updated version of SmPC reflecting changes to sections 4.3, 4.5 and 4.8 as well as change in MAH and update of format to QRD template.
Updated on 27/09/2005 and displayed until 24/09/2008
Reasons for adding or updating:
  • Addition of separate SPCs covering individual presentations

Active Ingredients/Generics

 
   metronidazole